Scouting report · NTRA

Matthew Rabinowitz, Ph.D.Founder

Co-founded Natera; CEO to January 2019, Executive Chairman since

Born / age
(52)
Role
Executive Chairman and Co-Founder
In the role
8 yr
Education
BS Stanford University
Front Office rank
not ranked yet
NTRA
Natera, Inc.Diagnostics
Title
Executive Chairman and Co-Foundersrc
In role
since 2019-01 (8 yr)
Stake value—no holding or price on file
—thin record

Scouting sheetas of 24 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design5548% performance-conditioned · revenue, margin, fcf, time only · 98% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
48%Pay at risk
98%Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
Matthew Rabinowitz, Ph.D.
Age
52src
Education
BS Engineering and Physics, Stanford Universitysrc
Founder
Yes

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
4,817,009 NTRA, 2026-03-15src
Share of company
3.39%
Traded, 12 months
bought $0, sold $124.0msrc
Last pay
$11.3m 2025src
Pay at risk
48%
Say-on-pay vote
98.0% forsrc
CEO pay ratio
101 : 1

What to weigh

Red flag 1

  • Related-party exposure: Natera holds about 19.1% of MyOme, which he founded and chairs and owns about 19.4% of. Natera bought another $10m of MyOme preferred in January 2026 and pays it royalties under a collaboration (immaterial in 2025). Sheena, his brother and a Sequoia affiliate (Lead Director Botha) are also connected. An independent board committee oversees the relationshipsrc

Watch 4

  • Family on the payroll: his brother is Chief Legal Officer and was paid $4.5m in 2025src
  • Personal defendant in a certified securities class action (class period 2020-02-26 to 2022-03-14). The complaint alleges he, Chapman and Brophy sold stock while holding material non-public information. Allegations, not findingssrc
  • Heavy seller: about $124m of stock sold in the last 12 months, including 200,000 shares under a plan adopted 2025-12-11, after exercising 300,000 options at $9.59 in March-April 2026src
  • Non-independent executive chair. The pay formula is fixed by contract (salary 50% of the CEO's, bonus target 85% of salary on company metrics, equity 80% of the CEO's). The proxy says the next chairman will be independentsrc

In their favour 1

  • Still the largest insider holder at 3.39%, and he bought shares in the open market in 2022src

Pay

Salary and otherBonus, stock, options, incentive

  • $9.0m2023
  • $9.8m2024
  • $11.3m2025
The table
YearSalaryBonusStockOptionsIncentiveOtherTotal
2023$401k$0$0$8.2m$367k$0$9.0msrc
2024$401k$0$9.0m$0$405k$0$9.8msrc
2025$426k$0$10.4m$0$474k$0$11.3msrc
Bonus pays on
Cash incentive target 85% of salary, 100% on company metrics (revenue 55%, product gross margin 35%, operating cash flow 10%); paid 131.1% for 2025 as fully vested RSUs
Long-term award pays on
By contract, equity worth 80% of the CEO's grant in the same mix: 50% PSUs on a three-year cumulative revenue goal, 50% time-based RSUs over four yearssrc
  • Pay at risk 48% performance-conditioned
  • Pays on returns revenue, margin, fcf, time only
  • Shareholder vote 98% for
  • Pay vs profit company lost money

CEO pay ratio 101 : 1

Career

  1. 2019 – now
    Naterasrc
    Executive Chairman
    Stepped down as CEO and President effective 2019-01-02 (8K-2019-01-08)
  2. 2015 – 2019
    Naterasrc
    Chairman of the board (and CEO)
    Chairman from May 2015
  3. 2005 – 2019
    Naterasrc
    Co-founder, Chief Executive Officer; director since 2005
    Took the company public in July 2015
  4. 2018 – 2019
    Harvard University, Department of Geneticssrc
    Visiting faculty
  5. 2004 – 2012
    Stanford Universitysrc
    Consulting professor
  6. 2003 – 2007
    Rosum Corporationsrc
    Chief Technology Officer
  7. 2000 – 2003
    Rosum Corporationsrc
    Chief Executive Officer
    Location-services technology company

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Family His brother Daniel Rabinowitz is Natera's Secretary and Chief Legal Officer, employed since July 2004; 2025 total compensation $4,524,992. This is the only family relationship among directors and officerssrc
  • Founder Co-founded Natera with director Jonathan Sheena. Also founder and board chairman of MyOme, Inc., in which he holds about 19.4% fully diluted as of 2026-03-31src
  • Boards Director or advisory-board member of several private technology companies (the proxy does not name them)src
  • Investing In 2022 he and his family trust bought about 470,000 Natera shares, through open-market purchases and option exercises (over $10m in two months), per the company's releasesrc
  • Personal Has said publicly that a family experience with prenatal diagnosis led him to start the companysrc
  • Legal Named as a defendant, with Natera, Chapman and Brophy, in the securities class action in the Western District of Texas (filed April 2022). The motion to dismiss was granted in part; the class is certifiedsrc

Sources11

  1. Filing Natera DEF 14A for the 2026-06-11 annual meeting (accession 0001104659-26-047770) · 2026-04-23
  2. Filing Natera 8-K Item 5.02, Rabinowitz resigns as CEO and President; Chapman appointed (0001104659-19-001251) · 2019-01-08
  3. Filing Natera 8-K Item 5.02, amended and restated employment agreement with Executive Chairman Rabinowitz, effective 2024-11-01 (0001104659-24-126348) · 2024-12-06
  4. Filing Natera 8-K Items 5.02/5.07, 2026 annual meeting results (0001604821-26-000003) · 2026-06-16
  5. Filing Natera 10-K for FY2025 (0001104659-26-020881): key-person risk factor, Item 9B 10b5-1 plan disclosures, Legal Proceedings note · 2026-02-27
  6. Filing SEC XBRL companyconcept us-gaap/NetIncomeLoss, CIK 1604821 (FY2025 10-K, 0001104659-26-020881) · 2026-02-27
  7. Filing Form 4, Matthew Rabinowitz (reporting CIK 1646382), 10b5-1 sales of 2026-09-14/15 (0001646382-26-000021); window totals summed over all 15 of his Form 4s filed 2025-10-22 to 2026-09-16 · 2026-09-16
  8. Filing Form 4, Matthew Rabinowitz, option exercises at $9.59 and 10b5-1 sales of 2026-03-12 to 03-16 (0001646382-26-000002) · 2026-03-16
  9. Web search result WebSearch: Kessler Topaz case page and amended complaint, Natera securities class action (W.D. Tex. 1:22-cv-00398); names Natera, Steve Chapman, Michael Brophy, Matthew Rabinowitz among defendants · 2026-09-24
  10. Web search result WebSearch: PR Newswire, 'Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera' (May 2022) · 2026-09-24
  11. Web search result WebSearch: Sequoia Capital 'Crucible Moments' podcast episode on Natera with Matthew Rabinowitz · 2026-09-24